A multivalent shigella vaccine and methods of making and using thereof
A multivalent Shigella vaccine with monovalent sOS conjugates addresses the challenge of broad serotype coverage by inducing immune responses against diverse Shigella strains, particularly in low- and middle-income countries, enhancing protection against diarrhea in infants and children.
Patent Information
- Application Number
- PCT/EP2025/080732
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-10-23
- Filing Date
- 2025-10-23
- Publication Date
- 2026-04-30
AI Technical Summary
There is a need for a vaccine that provides broad serotype coverage and is well-tolerated, immunogenic, and efficacious against moderate-to-severe diarrhea caused by diverse Shigella strains, particularly in infants and children under 5 years of age in low- and middle-income countries, as current vaccines lack sufficient protection against a wide range of circulating serotypes.
A multivalent Shigella vaccine composition comprising two or more monovalent synthetic oligosaccharide (sOS)-based Shigella conjugates, each conjugated to a carrier such as tetanus toxoid, targeting specific O-Ag repeating units from serotypes S.flexneri 2a, S.flexneri 3a, S.flexneri 6, and S. sonnei, with varying degrees of conjugation and attachment methods.
The vaccine induces robust immune responses across multiple Shigella serotypes, offering protection against a diverse array of strains and reducing the burden of shigellosis in vulnerable populations.